Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering is a promising biopharmaceutical company with a BUY rating, supported by their innovative Disease Cancelling Technology platform and strong computational biology capabilities. Despite facing risks in clinical trials and competition, their potential breakthrough cancer treatment, atebimetinib, and other drug pipelines indicate a positive outlook for long-term profitability in the future. With a price target of $14 and projected profitability in 2035, Immuneering is a prime investment opportunity in the biopharmaceutical industry.

Bears say

Immuneering is heavily focused on developing MEK inhibitors and other oncology programs, with some promising early results. However, their reliance on this area puts them at risk if these drugs fail in clinical trials. Their current financials suggest a strong cash position, but it is uncertain if they will be able to achieve their projected peak market shares and sales for their drugs.

Immuneering Corp (IMRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Immuneering Corp (IMRX) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.